Jeanne Tie
Led DYNAMIC, the first randomised trial to show ctDNA can safely guide who needs chemotherapy after colon cancer surgery.
Overview
Jeanne Tie led DYNAMIC, which showed that using ctDNA to decide adjuvant chemotherapy in stage II colon cancer halves chemotherapy use without worsening recurrence-free survival, the first randomised proof that ctDNA-guided de-escalation works. Her 2016 study established post-operative ctDNA as a powerful marker of residual disease. She now leads DYNAMIC-III and DYNAMIC-Rectal.
| Title | Journal | Year |
|---|---|---|
| Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer (DYNAMIC) | NEJM | 2022 |
| Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer | Science Translational Medicine | 2016 |
The blood test stratifies risk far better than stage or pathology. It supports treating ctDNA-positive patients and suggests ctDNA-negative patients gain little from chemotherapy, but because treatment was not randomised the de-escalation claim needs the randomised trials that are now under way.
For stage II colon cancer, where most patients are cured by surgery alone, a blood test can identify the minority who benefit from chemotherapy and spare everyone else its side effects. It does not yet prove that treating ctDNA-positive patients improves survival compared with not treating them.
Pages like this
not linked directly; found by shared links- IdeactDNA-guided adjuvant therapy as the default in stage II-III colon cancer
Shares GALAXY: tumour DNA in blood four weeks after bowel cancer surgery predicts relapse tenfold, DYNAMIC, DYNAMIC: a blood test safely halved chemotherapy use after surgery for stage II colon cancer, CIRCULATE-Japan (GALAXY / VEGA / ALTAIR).
- PersonAlberto Bardelli
Shares Liquid biopsy (ctDNA), Colorectal cancer and the tags ctdna, colorectal.
- IdeaFormally qualify tumour-DNA blood tests as a surrogate endpoint for adjuvant trials
Shares GALAXY: tumour DNA in blood four weeks after bowel cancer surgery predicts relapse tenfold, DYNAMIC, CIRCULATE-Japan (GALAXY / VEGA / ALTAIR), Signatera.
- IdeaStrip the platelet coat off travelling tumour cells in ctDNA-positive patients
Shares DYNAMIC, CIRCULATE-Japan (GALAXY / VEGA / ALTAIR), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- PairingctDNA MRD → adjuvant therapy decision
Shares DYNAMIC, DYNAMIC: a blood test safely halved chemotherapy use after surgery for stage II colon cancer, Signatera, MRD / molecular residual disease testing.
- IdeaA national residual-disease weather service: serial blood tests for every curatively treated patient, pooled
Shares DYNAMIC, Signatera, MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- PersonTakayuki Yoshino
Shares GALAXY: tumour DNA in blood four weeks after bowel cancer surgery predicts relapse tenfold, CIRCULATE-Japan (GALAXY / VEGA / ALTAIR), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- ProductOncodetect
Shares Signatera, MRD / molecular residual disease testing, Liquid biopsy (ctDNA), Colorectal cancer.